Questions Raised About Invokana Label Expansion For CV Risk Reduction

Experts are raising questions about FDA ' s decision to expand the label of the diabetes drug Invokana to reduce the risk of cardiovascular events.

Source: Forbes.com Healthcare News - November 1, 2018 Category: Pharmaceuticals Authors: Larry Husten, Contributor Tags: NYSE:LLY NYSE:JNJ Source Type: news